The first Precision Biology-based GLP-1 companion program, Digbi Care (™), gets even better by incorporating gut microbiome and genetic biomarkers that determine tolerability and efficacy of GLP-1 drugs. 

PALO ALTO, California.  News Provided by Digbi Health

Digbi Health, the leader in Precision Biology care, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its  GLP-1 telehealth program. Digbi Health introduced an advanced obesity test that includes genetic, blood glucose, gut microbiome biomarkers, and clinical GI helath assessment components to personalize nutritional and pharmacotherapy support, ensuring everyone receives the right care based on their biology and lifestyle.

Understanding the Different Causes of Obesity to Personalize Treatment

The causes of obesity, efficacy, and tolerability of GLP-1 medication vary widely among individuals based on their genetics, gut microbiome, and glucose metabolism. For some, obesity is primarily driven by insulin-related metabolic issues. For others, it stems from dysfunction of the gut-brain axis, which influences cravings and hunger regulation, as well as GLP-1 side effects such as nausea and diarrhea.

By isolating these different profiles, Digbi Health can tailor treatment  more precisely, leading to 3X better weight loss outcomes and 5X better drug tolerability than traditional one-size-fits-all GLP-1 lifestyle companion programs, which ignore the patient's biology, ethnicity, and gender.

Building Innovation: The First Precision Biology-Based Obesity Test

Following the successful launch of its GLP Compass(™), Digbi Health continues to innovate by expanding its obesity test capabilities in 2025. GLP Compass(™) provides members with clarity on their weight loss journey by determining who truly needs GLP-1 drugs versus those who can achieve sustainable weight loss through food-as-medicine. This ensures that patients avoid unnecessary medication, while employers and health plans incur fewer costs, and natural and sustainable health improvements are maximized.

2025 Expansions:

• GLP-1 Drug Responsiveness Prediction – Research indicates that 25% of individuals on GLP-1 drugs experience a weight loss of less than 5%, while 25% experience a weight loss of more than 15%. By analyzing glucose metabolism, genetic predispositions, and individual gut microbiome, this test predicts drug responsiveness and optimizes treatment modalities to ensure a uniform and effective response across individuals.
  
• GI Adverse Effect Risk Assessment—40% of patients on GLP-1 drugs discontinue the medication. Gastrointestinal adverse effects are the primary cause of discontinuation. The test enables the Digbi care team to anticipate and manage gastrointestinal side effects that commonly occur with GLP-1 medications. By anticipating risk factors, patients can work with the AI-supported Digbi care team to proactively manage nausea, abdominal flare-ups, and improve adherence, ultimately enhancing overall success with the therapy.
  
  
• GLP-1 Tapering Success Predictor—This first-of-its-kind tool identifies members who are ideal candidates for tapering or dose reduction based on over 150 parameters across lifestyle, genetics, and gut health. This ensures that members who taper off the drug maintain their weight long-term without GLP support.

Digbi developed GLP Compass using AI and millions of data points from the biology, food, medical, and lifestyle data of 10,000 patients over a 52-week period. It sets a new standard in obesity management and optimizing pharmacotherapy.

"Our goal is to provide personalized and AI-based nutrition-first care for the top food-related illnesses—Obesity, Type 2 diabetes, gastrointestinal disorders, and mental health," said Ranjan Sinha, Founder and CEO at Digbi Health. "By expanding our industry-leading obesity test, we reinforce our commitment to innovation and safety-first AI-based care."

About Digbi Health
Digbi is the first company to offer precision biology-based care to over 25 million people across eight health plans and large to medium-sized employers, all supported by food-as-medicine and a national telehealth clinic specializing in obesity, cardiometabolic, and gastrointestinal health. 

Digbi combines thousands of genetics, gut microbiome, CGM, blood biomarkers, and AI-powered insights to deliver personalized, nutrition-first care solutions to prevent and treat obesity, metabolic, and gastrointestinal issues in 40 languages.

Precision Biology is no longer the future of care. With +100 employers using Digbi Health, it's the new standard.

Contact:
Aniiket Sengar VP Marketing Operations
aniiket@digbihealth.com